Renaissance Technologies (RenTech)'s EBS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 656,047 shares of Emergent BioSolutions Inc. (EBS) worth $5.45 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in EBS, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2023, adding 547,300 shares. Largest reduction occurred in Q2 2024, reducing 717,553 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Emergent BioSolutions (EBS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Emergent BioSolutions (EBS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +78,900 | Add 13.67% | 656,047 | $8.30 |
| Q4 2025 | +58,900 | Add 11.37% | 577,147 | $12.36 |
| Q3 2025 | -171,400 | Reduce 24.85% | 518,247 | $8.82 |
| Q2 2025 | -70,600 | Reduce 9.29% | 689,647 | $6.38 |
| Q1 2025 | +94,400 | Add 14.18% | 760,247 | $4.86 |
| Q4 2024 | +140,900 | Add 26.84% | 665,847 | $9.56 |
| Q3 2024 | +351,200 | Add 202.13% | 524,947 | $8.35 |
| Q2 2024 | -717,553 | Reduce 80.51% | 173,747 | $6.82 |
| Q1 2024 | +344,000 | Add 62.85% | 891,300 | $2.53 |
| Q4 2023 | +547,300 | New Buy | 547,300 | $2.40 |
| Q1 2023 | -304,000 | Sold Out | 0 | $0.00 |
| Q4 2022 | +248,900 | Add 451.72% | 304,000 | $0.01 |
| Q3 2022 | -39,900 | Reduce 42.00% | 55,100 | $21.00 |
| Q2 2022 | -263,000 | Reduce 73.46% | 95,000 | $31.04 |
| Q1 2022 | +358,000 | New Buy | 358,000 | $41.06 |
| Q1 2021 | -62,100 | Sold Out | 0 | $0.00 |
| Q4 2020 | +17,996 | Add 40.80% | 62,100 | $89.60 |
| Q3 2020 | -340,520 | Reduce 88.53% | 44,104 | $103.32 |
| Q2 2020 | -238,377 | Reduce 38.26% | 384,624 | $79.08 |
| Q1 2020 | -141,100 | Reduce 18.47% | 623,001 | $57.86 |
| Q4 2019 | -220,210 | Reduce 22.37% | 764,101 | $53.95 |
| Q3 2019 | -366,200 | Reduce 27.12% | 984,311 | $52.28 |
| Q2 2019 | -627,891 | Reduce 31.74% | 1.35 M | $48.31 |
| Q1 2019 | +382,391 | Add 23.96% | 1.98 M | $50.52 |
| Q4 2018 | -275,300 | Reduce 14.71% | 1.6 M | $59.28 |
| Q3 2018 | -195,200 | Reduce 9.45% | 1.87 M | $65.83 |
| Q2 2018 | +198,600 | Add 10.63% | 2.07 M | $50.49 |
| Q1 2018 | +283,000 | Add 17.86% | 1.87 M | $52.65 |
| Q4 2017 | +432,300 | Add 37.51% | 1.58 M | $46.47 |
| Q3 2017 | +332,200 | Add 40.49% | 1.15 M | $40.45 |
| Q2 2017 | +117,700 | Add 16.75% | 820,411 | $33.91 |
| Q1 2017 | -180,800 | Reduce 20.46% | 702,711 | $29.04 |
| Q4 2016 | -294,600 | Reduce 25.01% | 883,511 | $32.84 |
| Q3 2016 | -96,100 | Reduce 7.54% | 1.18 M | $31.53 |
| Q2 2016 | +161,400 | Add 14.50% | 1.27 M | $28.12 |
| Q1 2016 | +161,200 | Add 16.94% | 1.11 M | $36.35 |
| Q4 2015 | +177,400 | Add 22.91% | 951,611 | $40.01 |
| Q3 2015 | +102,700 | Add 15.29% | 774,211 | $28.49 |
| Q2 2015 | +84,700 | Add 14.43% | 671,511 | $32.95 |
| Q1 2015 | +75,700 | Add 14.81% | 586,811 | $28.76 |
| Q4 2014 | -28,300 | Reduce 5.25% | 511,111 | $27.23 |
| Q3 2014 | -68,100 | Reduce 11.21% | 539,411 | $21.31 |
| Q2 2014 | -155,387 | Reduce 20.37% | 607,511 | $22.46 |
| Q1 2014 | +199,287 | Add 35.36% | 762,898 | $25.27 |
| Q4 2013 | -33,900 | Reduce 5.67% | 563,611 | $22.99 |
| Q3 2013 | -126,300 | Reduce 17.45% | 597,511 | $19.05 |
| Q2 2013 | +723,811 | Add 0.00% | 723,811 | $14.42 |
Renaissance Technologies (RenTech)'s Emergent BioSolutions Investment FAQs
Renaissance Technologies (RenTech) first purchased Emergent BioSolutions Inc. (EBS) in Q2 2013, acquiring 723,811 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Emergent BioSolutions Inc. (EBS) for 47 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Emergent BioSolutions Inc. (EBS) was in Q2 2013, adding 723,811 shares worth $10.44 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 656,047 shares of Emergent BioSolutions Inc. (EBS), valued at approximately $5.45 M.
As of the Q1 2026 filing, Emergent BioSolutions Inc. (EBS) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Emergent BioSolutions Inc. (EBS) was 2,066,511 shares, as reported at the end of Q2 2018.